Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05986604
Other study ID # TranS-C+MSI vs. TranS-C Alone
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date January 4, 2024
Est. completion date July 28, 2028

Study information

Verified date June 2024
Source University of California, Berkeley
Contact Allison Harvey, PhD
Phone 5106427138
Email aharvey@berkeley.edu
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Mental illness is often chronic, severe, and difficult to treat. Though there has been significant progress towards establishing effective and efficient interventions for psychological health problems, many individuals do not gain lasting benefits from these treatments. The Memory Support Intervention (MSI) was developed utilizing existing findings from the cognitive science literature to improve treatment outcomes. In this study, the investigators aim to conduct an open trial that includes individuals 50 years and older to assess if a novel version of the Memory Support Intervention improves sleep and circadian functioning, reduces functional impairment, and improves patient memory for treatment.


Description:

Life expectancy has increased drastically in the United States. Longer life is too often associated with illness, discomfort, disability, and dependency. Progress toward promoting health and well-being as we age must include the identification of novel treatment targets that are safe, powerful, inexpensive, and deployable. The proposed research will test one such target-patient memory for the contents of treatment. Over 5 years, we will recruit adults who are 50 years and older and who are experiencing sleep and circadian problems (n = 178, including 20% for attrition). Participants will be randomly allocated to TranS-C plus the MSI ("TranS-C+MSI") or TranS-C alone via eight 50-minute, weekly, individual sessions. Assessments will be conducted at baseline, post-treatment, and at 6- and 12-month follow-up (6FU and 12FU). Specific Aim 1: To evaluate if adding the MSI to TranS-C (a) improves sleep and circadian functioning, (b) improves daytime functioning, (c) improves well-being and (d) improves patient memory by comparing the effects of TranS-C+MSI vs. TranS-C alone. Hypothesis 1. Compared to TranS-C alone, people who receive TranS-C+MSI will improve more on all outcomes at post-treatment, 6FU and 12FU. Specific Aim 2: To evaluate if patient memory for treatment mediates the relation between treatment condition and sleep and circadian functioning. Hypothesis 2. TranS-C+MSI will be associated with better memory for treatment relative to TranS-C alone, and in turn, better memory for treatment will be associated with better sleep and circadian functioning immediately following treatment and at 6FU and 12FU. Specific Aim 3: To evaluate if subgroups hypothesized to derive added benefit from memory support moderate (a) patient memory for treatment and (b) treatment outcome. Hypothesis 3. Treatment effects for TranS-C+MSI will be larger at post-treatment for those who are older, have fewer years of education, poorer baseline cognitive functioning and more severe baseline sleep disruption and sleep-related impairment. Exploratory analyses will compare the treatments on (a) patient adherence as well as patient-rated treatment credibility and utilization of treatment elements and (b) provider-rated acceptability, appropriateness, and feasibility.


Recruitment information / eligibility

Status Recruiting
Enrollment 178
Est. completion date July 28, 2028
Est. primary completion date February 28, 2028
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 50 Years and older
Eligibility Inclusion criteria: 1. Aged 50 years and older; 2. English language fluency; 3. Experiencing a mobility impairment; 4. Low income; 5. Exhibit a sleep or circadian disturbance as determined by endorsing 4 "quite a bit" or 5 "very much" (or the equivalent for reverse scored items) on one or more PROMIS-SD questions. 6. 25-30 on the Montreal Cognitive Assessment, as a negative screen for cognitive impairment. 7. Able/willing to give informed consent. Exclusion criteria: 1. Severe untreated sleep disordered breathing (AHI>30) or moderate untreated sleep disordered breathing with severe daytime sleepiness (AHI of 15-30 and Epworth Sleepiness Scale >10); 2. Medical conditions that prevent a participant from comprehending and following the basic tenants of treatment (e.g., dementia) or that interfere with sleep in a manner that can't be addressed by a cognitive behavioral treatment (e.g., the Structured Clinical Interview for Sleep Disorders will be used to screen for narcolepsy, REM sleep behavior disorder) or that may preclude full participation (e.g., receipt of end of life care); 3. Homelessness; 4. Night shift work >2 nights per week in the past 3 months; 5. Substance abuse/dependence only if it makes participation in the study unfeasible; 6. Suicide risk sufficient to preclude treatment on an outpatient basis.

Study Design


Intervention

Behavioral:
Memory Support Intervention
The Memory Support Intervention is designed to improve patient memory for treatment and involves a series of specific procedures that support the encoding and retrieval stages of episodic memory. The memory support strategies are proactively, strategically and intensively integrated into treatment-as-usual to support encoding. Memory support is delivered alongside each 'treatment point', defined as a main idea, principle, or experience that the treatment provider wants the patient to remember or implement as part of the treatment.
Transdiagnostic Intervention for Sleep and Circadian Dysfunction
TranS-C aims to provide one protocol to treat a range of sleep and circadian problems because sleep and circadian problems are often not so neatly categorized and because the existing research provides few guidelines to treat more complex patients.

Locations

Country Name City State
United States University of California, Berkeley Berkeley California

Sponsors (1)

Lead Sponsor Collaborator
University of California, Berkeley

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Other WatchPAT One For participants who screen positive for obstructive sleep apnea, WatchPAT One will be offered to determine eligibility Baseline only
Other Adverse events checklist To assess any adverse events experienced as a result of participating in the study Only at post-treatment which is 8-10 weeks after the beginning of treatment
Other Montreal Cognitive Assessment (MoCA) A measure of cognitive functioning/cognitive impairments to determine eligibility Baseline only
Other Adapted Credibility Expectancy Questionnaire Measures the credibility and expectation of improvement from the treatment. At treatment Week 2 and at post-treatment which is 8-10 weeks after the beginning of treatment
Other Structured Clinical Interview for Sleep Disorders Measures sleep and circadian diagnoses according to DSM-5 Baseline only
Other Adapted Brief Disability Questionnaire A measure of functional impairment Baseline only
Primary Patient-Reported Outcomes Measurement Information System - Sleep Disturbance Assesses perceived functional impairments related to sleep problems using a self-report questionnaire. The minimum value is 8. The maximum value is 40. Higher scores mean more sleep disturbance (worse outcome). Change from baseline to post-treatment, which is 8-10 weeks after the beginning of treatment to 6-month follow-up to 12-month follow-up
Primary Sheehan Disability Scale Assesses functional impairment on a scale from 0 to 30, where higher scores mean higher impairment Change from baseline to post-treatment, which is 8-10 weeks after the beginning of treatment to 6-month follow-up to 12-month follow-up
Primary Satisfaction with Life Scale 5-item instrument designed to measure global cognitive judgements of satisfaction with one's life. Scores can range from 5-35 with higher scores indicating higher levels of satisfaction with life. Change from baseline to post-treatment, which is 8-10 weeks after the beginning of treatment to 6-month follow-up to 12-month follow-up
Secondary Patient-Reported Outcomes Measurement Information System - Sleep Related Impairment Assesses perceived functional impairments related to sleep problems in a self-report questionnaire. The minimum value is 16. The maximum value is 80. Higher scores mean more sleep related problems (worse outcome). Change from baseline to post-treatment, which is 8-10 weeks after the beginning of treatment to 6-month follow-up to 12-month follow-up
Secondary Positive and Negative Affect Scale Positive affect scores can range from 10-15, with higher scores representing higher levels of positive affect. Negative affect scores can range from 10-50, with lower scores representing lower levels of negative affect Change from baseline to post-treatment, which is 8-10 weeks after the beginning of treatment to 6-month follow-up to 12-month follow-up
Secondary WHODAS 2.0 A measure of functional impairment Change from baseline to post-treatment, which is 8-10 weeks after the beginning of treatment to 6-month follow-up to 12-month follow-up
Secondary Cognitive Failures Questionnaire Used to assess the frequency with which people experienced cognitive failures. Scores range from 0-100, with higher scores indicating higher levels of cognitive failures. Change from baseline to post-treatment, which is 8-10 weeks after the beginning of treatment to 6-month follow-up to 12-month follow-up
Secondary Epworth Sleepiness Scale Used to assess daytime sleepiness. Scores can range from 0-24 with higher scores indicating higher levels of daytime sleepiness. Change from baseline to post-treatment, which is 8-10 weeks after the beginning of treatment to 6-month follow-up to 12-month follow-up
Secondary Memory for Treatment: Cumulative recall Recall on the Patient Treatment Recall Task Week 4 of treatment as well as Post Treatment, defined as two weeks after the final therapy session (i.e. 8-10 weeks after the initial intake interview) to 6-month follow-up to 12-month follow-up]
Secondary Thoughts and Applications Task Measures how treatment points have generalized to the participant's thinking and functioning during every day life Week 4 of treatment as well as Post Treatment, defined as two weeks after the final therapy session (i.e. 8-10 weeks after the initial intake interview) to 6-month follow-up to 12-month follow-up]
Secondary Adapted Utilization Scale 19-item; 0-4 scale. Scores can range from 0 to 76 (Higher score means more utilization). Change from baseline to post-treatment, which is 8-10 weeks after the beginning of treatment to 6-month follow-up to 12-month follow-up
Secondary Composite Sleep Health Score Composite Sleep Health Score which is defined as the sum of scores on 6 sleep health dimensions: Regularity (Midpoint fluctuation), Satisfaction (Sleep quality question on PROMIS-SD), Alertness (Daytime sleepiness question on PROMIS-SRI), Timing (Mean midpoint), Efficiency (Sleep efficiency) and Duration (Total Sleep Time). Change from baseline to post-treatment, which is 8-10 weeks after the beginning of treatment to 6-month follow-up to 12-month follow-up
Secondary Mean sleep efficiency (Daily Sleep Diary) Daily Sleep Diary mean for sleep efficiency (total sleep time/time in bed X 100) Change from baseline to post-treatment, which is 8-10 weeks after the beginning of treatment to 6-month follow-up to 12-month follow-up
Secondary Mean total wake time (Daily Sleep Diary) Daily Sleep Diary mean for total wake time defined as sleep onset latency + wake after sleep onset + Early morning awakening Change from baseline to post-treatment, which is 8-10 weeks after the beginning of treatment to 6-month follow-up to 12-month follow-up
Secondary Mean for total sleep time (Daily Sleep Diary) Daily Sleep Diary mean for total sleep time Change from baseline to post-treatment, which is 8-10 weeks after the beginning of treatment to 6-month follow-up to 12-month follow-up
Secondary Mean for total wake time (Actigraphy) Actigraphy mean for total wake time defined as sleep onset latency + wake after sleep onset + early morning awakening Change from baseline to post-treatment, which is 8-10 weeks after the beginning of treatment
Secondary Mean for total sleep time (Actigraphy) Actigraphy mean for total sleep time Change from baseline to post-treatment, which is 8-10 weeks after the beginning of treatment
Secondary Mean for daytime activity (Actigraphy) Actigraphy mean for daytime activity Change from baseline to post-treatment, which is 8-10 weeks after the beginning of treatment
Secondary Provider level: Acceptability of Intervention Measure Assess provider perceptions of the acceptability of the treatment intervention using a self-report questionnaire Through therapy completion, an average of 8 weeks following baseline
Secondary Provider level: Appropriateness Intervention Measure Assesses provider perceptions of the appropriateness of the treatment intervention using a self-report questionnaire Through therapy completion, an average of 8 weeks following baseline
Secondary Provider level: Feasibility of Intervention Measure Assesses provider perceptions of the feasibility of the intervention using a self-report questionnaire Through therapy completion, an average of 8 weeks following baseline
Secondary Provider level: Provider-rated TranS-C Checklist A measure of the TranS-C elements that are delivered. This is completed by the therapist at the end of every treatment session Every treatment session which is 8 sessions, spaced one week apart for approximately 8-10 weeks
Secondary Provider level: Memory Support Treatment Provider Checklist A measure of memory support delivered. This is completed by the therapist at the end of every treatment session Every treatment session which is 8 sessions, spaced one week apart for approximately 8-10 weeks
Secondary Provider level: Patient adherence via the TARS A measure of patient treatment adherence completed by the therapist at the end of every treatment session Every treatment session which is 8 sessions, spaced one week apart for approximately 8-10 weeks
Secondary Provider level: Memory Support Rating Scale, total amount Assesses the total amount of memory support used by a provider via coding of session tapes Randomly selected therapy tapes
Secondary Provider level: Memory Support Rating Scale, number of types Assesses the number of types of memory support used by a provider via coding of session tapes Randomly selected therapy tapes
See also
  Status Clinical Trial Phase
Recruiting NCT05820919 - Enhancing Sleep Quality for Nursing Home Residents With Dementia - R33 Phase N/A
Recruiting NCT04786314 - The Effect of Hot and Cold Water Application on Pregnant Women With Restless Leg Syndrome N/A
Recruiting NCT05775731 - Markers of Inflammation and of the Pro-thrombotic State in Hospital Shift and Day Workers
Recruiting NCT03326765 - Characterizing Sleep Disorders in Children and Adults With Tuberous Sclerosis Complex (TSC) N/A
Completed NCT03673397 - The Acute Effect of Aerobic Exercise on Sleep in Patients With Depression N/A
Completed NCT03903263 - Sleep Disturbances in Dermatology Patients
Not yet recruiting NCT06012513 - Sleep Disorders and Quality of Life in Patients With Multiple Sclerosis
Not yet recruiting NCT05950932 - Effects of Melissa Extract on Sleep Characteristics Phase 4
Completed NCT01463839 - Sleep Disorder and Oral Habits in Children N/A
Completed NCT00940589 - Efficacy of Circadin® 2 mg in Patients With Mild to Moderate Alzheimer Disease Treated With AChE Inhibitor Phase 2
Recruiting NCT06093633 - A Prospective Study to Evaluate the WP in Comparison to PSG in Patients Suspected of Sleep Disorders
Completed NCT06108115 - Smartphone-Based Intervention for Sleep Disturbance in Individuals Recovering From Alcohol Use Disorder N/A
Completed NCT05511818 - Radicle Rest: A Study of Cannabinoids on Sleep and Health Outcomes N/A
Active, not recruiting NCT04291014 - Light Therapy for PD - Dose Selection N/A
Completed NCT04560595 - Remote Guided Caffeine Reduction N/A
Completed NCT06008470 - Investigation of Respiratory Muscle Strength, Exercise Capacity, Physical Activity and Sleep Quality Level in Individuals With Covid-19 Infection
Recruiting NCT06129942 - Light Therapy in Parkinson's Disease N/A
Recruiting NCT04318067 - Melatonin in ADHD and Sleep Problems Phase 4
Completed NCT03532269 - Validation of the Sleep Assessment Algorithm in the Medical Application Nightly N/A
Completed NCT03857802 - Efficiency of a Nursing Intervention in Sleep Hygiene N/A